Ikris Pharma
About Us Named Patient Program
Cities We Serve Contact Us
Orelabrutinib

Sourced directly from the authorized manufacturer network to ensure authenticity and quality.

Ready to proceed? Order Orelabrutinib on our secure patient portal to submit your prescription, upload documents and track your approval status.

Orelabrutinib

Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.

Medicine Name: Orelabrutinib
Generic Name (API): Orelabrutinib
Dosage Form & Strength: 50 mg
Route: Oral
Drug Class: Bruton's tyrosine kinase (BTK) inhibitor

Manufacturer / Innovator:

Beijing InnoCare Pharma Tech Co., Ltd. (InnoCare Pharma)

Regulatory Approval:

  • NMPA (China)
  • HSA (Singapore)
  • TGA (Australia
  • provisional)
Family enjoying life with Named Patient Program access

Your Trustworthy Partner For Named Patient Program

  • your trusted partner for named patient program

    Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.

  • 100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.

    100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.

  • Medicines sourced from authorized manufacturers with full batch traceability

    Medicines sourced from authorized manufacturers with full batch traceability.

  • EU-GDP Compliant Warehousing for secure, quality-controlled global distribution.

    EU-GDP compliant warehousing for secure, quality-controlled global distribution.

  • Temperature-Controlled Logistics for Safe and Timely Delivery

    Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.

GDP Compliant View Certificate
Licensed Wholesale distributor View Certificate

What Is Orelabrutinib Used For?

Orelabrutinib is a once-daily tablet for certain B-cell blood cancers: chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL). It was discovered by InnoCare Pharma, a company listed in Hong Kong and Shanghai, and is sold in China as 宜诺凯 (Yinuokai®). The Chinese marketing licence is held by 北京诺诚健华医药科技有限公司 (Beijing InnoCare Pharma Tech Co., Ltd.). In Singapore and Australia the same medicine carries the name Hibruka®.

China's National Medical Products Administration (NMPA) first gave it conditional approval on 25 December 2020 and has added uses since then. It is now approved in China for adults with:

  • CLL/SLL as a single medicine, including people who have not been treated before (added April 2025)
  • CLL/SLL after at least one earlier treatment
  • Mantle cell lymphoma after at least one earlier treatment
  • Marginal zone lymphoma after at least one earlier treatment (added April 2023)

Which of these fits a particular patient, and when, is a decision for the treating haematologist or haemato-oncologist. You can see other imported medicines for these cancers in our lymphoma treatment section.

How It Works

B cells pass growth and survival signals through a pathway called the B-cell receptor pathway. An enzyme in that chain, Bruton's tyrosine kinase (BTK), stays overactive in many B-cell cancers and helps the abnormal cells keep multiplying. This medicine binds to BTK permanently and switches it off, which slows or stops those cells. It was designed to hit BTK very selectively, so that fewer other enzymes in the body are affected.

What the Trials Showed

Untreated CLL/SLL: a phase 3 trial in China (NCT04578613) randomised 192 adults to this tablet or to chemoimmunotherapy (a chemotherapy tablet plus an antibody drip). After a median of 21.4 months:

  • The risk of the disease growing or death fell by 68% (hazard ratio 0.32). Median progression-free survival had not been reached on the tablet, against 19.4 months in the comparison group.
  • Overall response: 90.1% versus 79.2%
  • Serious (grade 3 or higher) treatment-related side effects: 35.2% versus 60.2%

Mantle cell lymphoma after earlier treatment: in two single-arm studies with 129 patients taking 150 mg once a day, an independent review found that 76.0% responded and 35.7% had a complete response.

Marginal zone lymphoma after earlier treatment: among 90 patients with centrally confirmed MZL, 58.9% responded (11.1% completely). The median response lasted 34.3 months, and 82.8% were free of progression at one year.

Recommended Dosage

  • Usual dose: 150 mg (three 50 mg tablets) by mouth once a day. This is the dose on the Singapore and Australian labels and the dose used in the lymphoma trials.
  • Food: it can be taken with or without a meal, at about the same time each day
  • How to take it: swallow the tablets whole with water; do not break, crush or chew them
  • Missed dose: take it as soon as you remember only if the next dose is at least 8 hours away; otherwise skip it and never double up
  • Dose changes: after serious side effects the doctor pauses treatment and may restart at 150, 100 or 50 mg depending on how often the problem occurs. Lower doses are also used with moderate liver problems (100 mg) and with some interacting medicines.
  • How long: treatment continues until the disease progresses or side effects become unacceptable

This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.

Warnings and Precautions

Who should not take it: people with severe liver impairment, and anyone who has had a serious allergic reaction to the medicine or its ingredients. The safety figures below come from 630 patients with blood cancers who took it on its own in clinical trials.

  • Bleeding: bruising, small skin spots or other bleeding occurred in 31.7%, and serious bleeding in 2.1%; fatal bleeding has been reported. Blood thinners and anti-platelet medicines add to the risk. The tablets are usually stopped at least 3 days before and 7 days after surgery, and stopped for good after any bleeding in the brain.
  • Infections: serious infections, mostly pneumonia, affected 24.1%, and hepatitis B has flared up again in a small number of people. A hepatitis B test is done before starting, and any active infection should be controlled first. Report fever promptly.
  • Low blood counts: severe drops in neutrophils (12.7%), platelets (7.0%) and red cells (6.8%) were seen, so full blood counts are checked regularly.
  • Blood pressure: high blood pressure occurred in 10.3% (4.1% severe). Blood pressure should be checked during treatment, especially in people who already have hypertension.
  • Heart rhythm: rhythm changes were reported in 10.9%, mostly minor such as extra beats or QT prolongation (3.9%); atrial fibrillation or flutter occurred in 1.1%. Palpitations, dizziness, fainting or breathlessness need an ECG.
  • Second cancers: 4.4% developed another cancer, most often skin cancer (1.4%), so sun protection is advised.

Common side effects in patients with mantle cell lymphoma (129 people) were low platelets (27.9%), anaemia (25.6%), colds and other upper airway infections (24.8%), low neutrophils (22.5%), rash (21.7%), diarrhoea (20.2%), high blood sugar (20.2%), high blood pressure (19.4%) and pneumonia (18.6%).

Other points: the liver enzyme CYP3A breaks it down. Strong or moderate blockers of this enzyme (some antifungals, antibiotics and HIV medicines) mean a lower dose, and strong boosters (such as some epilepsy medicines and St John's wort) should be avoided, so share a full medicine list with the doctor. Women who could become pregnant should use effective contraception during treatment and for at least 1 month afterwards; men should avoid fathering a child during treatment and for 3 months afterwards. Breastfeeding is not advised during treatment and for at least 2 weeks after the last dose. Safety in children has not been established.

How to Access Orelabrutinib in India: A 6-Step Process

Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.

Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.

Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.

Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.

Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.

Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.

Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.

Documentation & Availability

What documents are required to import Orelabrutinib to India?

The tablets are brought in for one named patient, through the patient or the treating hospital, under India's rules on importing unapproved medicines for personal use. These papers are usually needed:

  • A prescription from a haematologist or oncologist that states the daily dose
  • A biopsy, flow cytometry or pathology report confirming CLL/SLL, mantle cell or marginal zone lymphoma
  • A short treatment summary showing earlier therapies, if any, and recent blood counts, liver tests and hepatitis B status
  • Government-issued photo ID of the patient

How is the order confirmed?

Once we have checked a valid prescription and, where required, the import permit has been issued.

Is Orelabrutinib available in India?

No. CDSCO has not approved it, which means no Indian chemist can sell it. Regulators that have cleared it are those of China, Singapore (for mantle cell and marginal zone lymphoma) and Australia (provisional approval for mantle cell lymphoma). The US FDA has not approved it, and we found no European approval.

Doctors can still request it through the Named Patient Program (NPP), which lets a medicine without Indian registration be imported for a single patient on prescription. For CLL, families also ask us about lisaftoclax, a China-approved CLL tablet that works in a different way.

It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.

Sourcing & Delivery

NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. The tablets are kept in their sealed original bottles and stored as directed on the pack; the Australian label asks for storage below 30°C, protected from light, with the lid closed. Parcels travel under temperature-controlled shipping which keeps the bottles away from high heat during transit. At the usual 150 mg dose a patient takes three tablets a day, about 90 a month, and we time each shipment so the next month's tablets arrive before the current bottle runs out. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.

For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.

Availability Across Major Cities in India

BTK treatment is taken every day, often for years, so a steady monthly supply matters more than a one-off delivery. With the paperwork complete, deliveries go to the cities named here and to many other places.

Delhi

Lymphoma and CLL clinics in Delhi can get the tablets quickly, since every parcel leaves from our New Delhi base.

Mumbai

Haemato-oncologists in Mumbai can email the biopsy report and prescription, and we deliver to the home or the hospital pharmacy.

Bangalore

For families in Bangalore, we share a written quote and the expected arrival date before anything is ordered.

Chennai

Patients in Chennai on long-term BTK treatment can have each month's supply timed around their blood-count visits.

Hyderabad

Doctors in Hyderabad treating mantle cell or marginal zone lymphoma can request the tablets once the diagnosis is documented.

Kolkata

For Kolkata and the north-east, monthly parcels are couriered from Delhi with tracking details sent by message.

Pune

Families in Pune can set up a repeat supply so that the once-daily dose is never interrupted.

Ahmedabad

Haematologists in Ahmedabad can send the hepatitis B result and treatment summary, and we tell them if any paper is still missing.

Vellore

Patients followed up in Vellore can have the bottles delivered to the hospital to match their review dates.

Chandigarh

Haematologists in Chandigarh who follow patients from across the northern states can have the next bottle dispatched before the review date.

Lucknow

In Lucknow, families choose between home delivery and delivery to the treating cancer centre.

Kochi

For patients across Kerala, parcels go to Kochi, Thrissur or the town closest to home.

Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.

Author Details

Nitin Goswami

Written By

Nitin Goswami

Deputy Manager – Content & Social Media, Ikris Pharma Network

Sources: NMPA • CDSCO

Dr. Chirag C Shah

Medically Reviewed By

Dr. Chirag C Shah

MBBS

Last Updated: 20 November 2026

More Hematology Medicines

TRUSTED BY HEALTHCARE PROFESSIONALS & HOSPITALS

Need Help
Accessing Medicines?

Our specialists are here to guide you through every step of the medicine access process.

Let's us help!

Send us a message

Read how to access medicines

Read More arrow icon

Frequently Asked
Questions

Read More
Meet the NPP Assistant: ask us anything about NPP